Active	Status	Sponsor type	Region	Phase	Filter
24 Active 2 Inactive 26 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   - « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   Show only changed items Enrollment:

Advanced Filters

24 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Barber, Neil
ACCTUATE, NCT05848037: Assessment of CymActive™ Catheter Technology for UrinAry ReTention and AcceptancE (The Study)	Recruiting	N/A	60	Europe	cymactive™ catheter device (CCD), Foley-type catheter device	Ingenion Medical Limited, Ingenion Medical Limited	Urinary Retention	12/25	12/25
CLEAR, NCT04338776: Comparing UroLift Experience Against Rezūm	Active, not recruiting	N/A	120	Europe, US	UroLift, Rezum	NeoTract, Inc.	Benign Prostatic Hyperplasia	05/25	12/25
NCT04757116: Post-Market Study to Assess iTind Safety in Comparison to UroLift	Recruiting	N/A	206	Europe, US	iTind, UroLift	Olympus Corporation of the Americas	Benign Prostatic Hyperplasia (BPH)	12/25	12/30
AUR87A, NCT04006405: AURORAX-0087A: GAG Scores for Surveillance of Recurrence in Leibovich Points ≥5 Non-metastatic ccRCC	Active, not recruiting	N/A	280	Europe, Canada, US	GAG score	Elypta	Clear Cell Renal Cell Carcinoma	05/25	12/25
NCT04658056: UK Post-market Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue	Not yet recruiting	N/A	46	Europe		PROCEPT BioRobotics	Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms	01/22	02/22
Nelson, Amy
NCT06186765: F15 Recharge Free Axonics SNM System Clinical Study	Recruiting	N/A	130	Europe, US	Axonics SNM System (Model 4101)	Axonics, Inc.	Urinary Urge Incontinence (UUI), Urinary Frequency (UF), Fecal Incontinence (FI)	08/25	06/26
NCT06217328: RESTORE: An RCT to Evaluate the Efficacy of the Revi System	Recruiting	N/A	150	US	Revi System Treatment, Revi System - Delayed Activation	BlueWind Medical	Urinary Urge Incontinence	05/26	05/27
APEX, NCT06560476: OPtilume™ BPH Catheter SystEm for Treatment of Men eXperiencing Symptomatic BPH	Recruiting	N/A	500	US	Data collection	Urotronic Inc.	Benign Prostatic Hyperplasia	03/27	03/27
ESSENCE, NCT05882318: Effectiveness of eCoin at Sensory and Subsensory Amplitudes	Completed	N/A	47	US	eCoin Peripheral Neurostimulator System	Valencia Technologies Corporation	Urge Incontinence	04/24	05/24
PROGECT, NCT02302742: Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry	Recruiting	N/A	1500	US		University of Kansas Medical Center	Breast Cancer, Hereditary Breast and Ovarian Cancer	12/24	12/25
NCT04757116: Post-Market Study to Assess iTind Safety in Comparison to UroLift	Recruiting	N/A	206	Europe, US	iTind, UroLift	Olympus Corporation of the Americas	Benign Prostatic Hyperplasia (BPH)	12/25	12/30
WATER IV PCa, NCT06651632: WATER IV Prostate Cancer	Recruiting	N/A	280	Europe, Canada, US, RoW	Aquablation Therapy, Radical Prostatectomy	PROCEPT BioRobotics	Localized Prostate Cancer	07/27	01/37
NCT02577302: CAN-Stim Compared to SNS in Treatment of Urinary Urgency Incontinence With Wireless Neuromodulation Technology	Recruiting	N/A	200	US	CAN-Stim - Protect CAN-Stim System, SNS - InterStim® System	Uro Medical Corporation	Urinary Incontinence, Urge	10/25	10/25
Krane, Louis
NCT04757116: Post-Market Study to Assess iTind Safety in Comparison to UroLift	Recruiting	N/A	206	Europe, US	iTind, UroLift	Olympus Corporation of the Americas	Benign Prostatic Hyperplasia (BPH)	12/25	12/30
Talaty, Pooja
NCT06062875: Effects of TNF Blockade on Human BPH/LUTS	Recruiting	2	70	US	Adalimumab, Placebo will be administered subcutaneously every 2 weeks, for a total of 6 injections.	NorthShore University HealthSystem, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Benign Prostatic Hyperplasia (BPH)	04/28	06/28
PRESERVE, NCT04972097: Pivotal Study of the NanoKnife System for the Ablation of Prostate Tissue	Completed	N/A	121	US	Irreversible Electroporation, The NanoKnife System	Angiodynamics, Inc.	Prostate Cancer	08/24	08/24
GenBx, NCT05295407: Performance of Inherited Risk Assessment for Predicting Prostate Cancer From Prostate Biopsy	Recruiting	N/A	1000	US	Genetic Assessment	NorthShore University HealthSystem, Northwestern University, Johns Hopkins University, GoPath Diagnostics	Prostate Cancer	12/24	12/25
NCT04757116: Post-Market Study to Assess iTind Safety in Comparison to UroLift	Recruiting	N/A	206	Europe, US	iTind, UroLift	Olympus Corporation of the Americas	Benign Prostatic Hyperplasia (BPH)	12/25	12/30
WATER IV PCa, NCT06651632: WATER IV Prostate Cancer	Recruiting	N/A	280	Europe, Canada, US, RoW	Aquablation Therapy, Radical Prostatectomy	PROCEPT BioRobotics	Localized Prostate Cancer	07/27	01/37
NCT06054867: PRCT002 PRostate Cancer Treatment With the AQUABEAM Robotic System	Active, not recruiting	N/A	22	US	Robotic Waterjet Treatment, Aquablation therapy	PROCEPT BioRobotics	Localized Prostate Cancer	04/25	04/25
NCT06051942: PRCT001 Aquablation theraPy Outcomes in pRostate Cancer patienTs	Recruiting	N/A	125	US, RoW	Robotic Waterjet Treatment, Aquablation therapy	PROCEPT BioRobotics	Benign Prostatic Hyperplasia, Localized Prostate Cancer	08/25	05/26
NCT05898932: Enhanced Clinical Decisions for Management of Benign Prostatic Hyperplasia Using Patient-Reported Outcomes	Recruiting	N/A	300	US	Medical Management, Surgical Management	Northwestern University, NorthShore University HealthSystem, University of Chicago	Benign Prostatic Hyperplasia	08/26	08/26
NCT05608694: MRI Screening in Men at High Risk of Developing Prostate Cancer	Recruiting	N/A	250	US	Prostate MRI	University of Chicago	Prostate Cancer Screening	03/37	03/39
Edwards, Alexander
NCT04757116: Post-Market Study to Assess iTind Safety in Comparison to UroLift	Recruiting	N/A	206	Europe, US	iTind, UroLift	Olympus Corporation of the Americas	Benign Prostatic Hyperplasia (BPH)	12/25	12/30

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Barber, Neil
ACCTUATE, NCT05848037: Assessment of CymActive™ Catheter Technology for UrinAry ReTention and AcceptancE (The Study)	Recruiting	N/A	60	Europe	cymactive™ catheter device (CCD), Foley-type catheter device	Ingenion Medical Limited, Ingenion Medical Limited	Urinary Retention	12/25	12/25
CLEAR, NCT04338776: Comparing UroLift Experience Against Rezūm	Active, not recruiting	N/A	120	Europe, US	UroLift, Rezum	NeoTract, Inc.	Benign Prostatic Hyperplasia	05/25	12/25
NCT04757116: Post-Market Study to Assess iTind Safety in Comparison to UroLift	Recruiting	N/A	206	Europe, US	iTind, UroLift	Olympus Corporation of the Americas	Benign Prostatic Hyperplasia (BPH)	12/25	12/30
AUR87A, NCT04006405: AURORAX-0087A: GAG Scores for Surveillance of Recurrence in Leibovich Points ≥5 Non-metastatic ccRCC	Active, not recruiting	N/A	280	Europe, Canada, US	GAG score	Elypta	Clear Cell Renal Cell Carcinoma	05/25	12/25
NCT04658056: UK Post-market Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue	Not yet recruiting	N/A	46	Europe		PROCEPT BioRobotics	Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms	01/22	02/22
Nelson, Amy
NCT06186765: F15 Recharge Free Axonics SNM System Clinical Study	Recruiting	N/A	130	Europe, US	Axonics SNM System (Model 4101)	Axonics, Inc.	Urinary Urge Incontinence (UUI), Urinary Frequency (UF), Fecal Incontinence (FI)	08/25	06/26
NCT06217328: RESTORE: An RCT to Evaluate the Efficacy of the Revi System	Recruiting	N/A	150	US	Revi System Treatment, Revi System - Delayed Activation	BlueWind Medical	Urinary Urge Incontinence	05/26	05/27
APEX, NCT06560476: OPtilume™ BPH Catheter SystEm for Treatment of Men eXperiencing Symptomatic BPH	Recruiting	N/A	500	US	Data collection	Urotronic Inc.	Benign Prostatic Hyperplasia	03/27	03/27
ESSENCE, NCT05882318: Effectiveness of eCoin at Sensory and Subsensory Amplitudes	Completed	N/A	47	US	eCoin Peripheral Neurostimulator System	Valencia Technologies Corporation	Urge Incontinence	04/24	05/24
PROGECT, NCT02302742: Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry	Recruiting	N/A	1500	US		University of Kansas Medical Center	Breast Cancer, Hereditary Breast and Ovarian Cancer	12/24	12/25
NCT04757116: Post-Market Study to Assess iTind Safety in Comparison to UroLift	Recruiting	N/A	206	Europe, US	iTind, UroLift	Olympus Corporation of the Americas	Benign Prostatic Hyperplasia (BPH)	12/25	12/30
WATER IV PCa, NCT06651632: WATER IV Prostate Cancer	Recruiting	N/A	280	Europe, Canada, US, RoW	Aquablation Therapy, Radical Prostatectomy	PROCEPT BioRobotics	Localized Prostate Cancer	07/27	01/37
NCT02577302: CAN-Stim Compared to SNS in Treatment of Urinary Urgency Incontinence With Wireless Neuromodulation Technology	Recruiting	N/A	200	US	CAN-Stim - Protect CAN-Stim System, SNS - InterStim® System	Uro Medical Corporation	Urinary Incontinence, Urge	10/25	10/25
Krane, Louis
NCT04757116: Post-Market Study to Assess iTind Safety in Comparison to UroLift	Recruiting	N/A	206	Europe, US	iTind, UroLift	Olympus Corporation of the Americas	Benign Prostatic Hyperplasia (BPH)	12/25	12/30
Talaty, Pooja
NCT06062875: Effects of TNF Blockade on Human BPH/LUTS	Recruiting	2	70	US	Adalimumab, Placebo will be administered subcutaneously every 2 weeks, for a total of 6 injections.	NorthShore University HealthSystem, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Benign Prostatic Hyperplasia (BPH)	04/28	06/28
PRESERVE, NCT04972097: Pivotal Study of the NanoKnife System for the Ablation of Prostate Tissue	Completed	N/A	121	US	Irreversible Electroporation, The NanoKnife System	Angiodynamics, Inc.	Prostate Cancer	08/24	08/24
GenBx, NCT05295407: Performance of Inherited Risk Assessment for Predicting Prostate Cancer From Prostate Biopsy	Recruiting	N/A	1000	US	Genetic Assessment	NorthShore University HealthSystem, Northwestern University, Johns Hopkins University, GoPath Diagnostics	Prostate Cancer	12/24	12/25
NCT04757116: Post-Market Study to Assess iTind Safety in Comparison to UroLift	Recruiting	N/A	206	Europe, US	iTind, UroLift	Olympus Corporation of the Americas	Benign Prostatic Hyperplasia (BPH)	12/25	12/30
WATER IV PCa, NCT06651632: WATER IV Prostate Cancer	Recruiting	N/A	280	Europe, Canada, US, RoW	Aquablation Therapy, Radical Prostatectomy	PROCEPT BioRobotics	Localized Prostate Cancer	07/27	01/37
NCT06054867: PRCT002 PRostate Cancer Treatment With the AQUABEAM Robotic System	Active, not recruiting	N/A	22	US	Robotic Waterjet Treatment, Aquablation therapy	PROCEPT BioRobotics	Localized Prostate Cancer	04/25	04/25
NCT06051942: PRCT001 Aquablation theraPy Outcomes in pRostate Cancer patienTs	Recruiting	N/A	125	US, RoW	Robotic Waterjet Treatment, Aquablation therapy	PROCEPT BioRobotics	Benign Prostatic Hyperplasia, Localized Prostate Cancer	08/25	05/26
NCT05898932: Enhanced Clinical Decisions for Management of Benign Prostatic Hyperplasia Using Patient-Reported Outcomes	Recruiting	N/A	300	US	Medical Management, Surgical Management	Northwestern University, NorthShore University HealthSystem, University of Chicago	Benign Prostatic Hyperplasia	08/26	08/26
NCT05608694: MRI Screening in Men at High Risk of Developing Prostate Cancer	Recruiting	N/A	250	US	Prostate MRI	University of Chicago	Prostate Cancer Screening	03/37	03/39
Edwards, Alexander
NCT04757116: Post-Market Study to Assess iTind Safety in Comparison to UroLift	Recruiting	N/A	206	Europe, US	iTind, UroLift	Olympus Corporation of the Americas	Benign Prostatic Hyperplasia (BPH)	12/25	12/30